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Background: Neoadjuvant Chemotherapy (NC) including trastuzumab induces a high rate of pathological
Complete Responses (pCR) in patients with locally advanced HER2-overexpressing Breast Cancer (BC), but is penalized
by a severe cardiotoxicity when combined with anthracyclines. A phase II study was designed to assess whether an
anthracycline-free NC regimen based on the early addition of trastuzumab to paclitaxel may increase the pCR rate
without inducing severe cardiotoxicity in patients with locally advanced HER2-overexpressing BC. Immunomonitoring
was performed to assess the contribution of patients’ immunological background to the induction of clinical responses.
Methods: Stage II-III HER2-positive BC patients received 24 weeks paclitaxel and trastuzumab NC, followed by 1 year
adjuvant trastuzumab ± hormonal and/or radio-therapy. Assessment of pCR rate was the primary endpoint. A
group of HER2-negative BC patients treated with neoadjuvant taxanes and anthracyclines was included. Serum
levels of 10 cytokines and the efficiency of trastuzumab-mediated antibody-dependent cell cytotoxicity (ADCC)
were monitored in vitro every 3 months.
Results: From July 2006 to February 2013, we enrolled 109 patients including 46 evaluable HER2-positive cases.
A pCR rate of 50% was reached and no severe cardiotoxicity occurred. Serum cytokine profiling revealed only an
IL-10 decrease (P = 0.02) in patients achieving a partial response, while HER2-negative patients disclosed marked
cytokines changes. Compared to the unfavourable F/F genotype, patients carrying the V allele in the FcγRIIIa-158
polymorphism showed a higher efficacy of trastuzumab-ADCC throughout treatment (P ≤0.05).
Conclusions: In the absence of anthracyclines, trastuzumab and paclitaxel induced a high rate of pCR, exploiting the
synergy between the immunomodulating properties of these drugs and the retained immunological proficiency of
patients with HER2-overexpressing BC.
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Trastuzumab-containing neoadjuvant chemotherapy (NC)
has significantly changed the standard of care for locally
advanced HER2-positive breast cancer (BC) patients, dem-
onstrating the ability to increase pathological Complete Re-
sponse (pCR) rates up to 65% [1]. Despite their efficacy,
however, clinically active NC regimens containing both
anthracyclines and trastuzumab are often burdened by car-
diotoxicity as a limiting side effect, which still constitutes
an open issue [2,3]. Conversely, in the NOAH trial, despite
the concurrent use of doxorubicin, paclitaxel and trastuzu-
mab, incidence of symptomatic cardiac failure was low
(<2%) [3,4]; however, long-term data on cardiotoxicity are
still lacking.
Available evidence indicates that HER2-positive BC
patients achieving pCR after NC have better relapse-free
and survival rates compared with those showing partial
responses [5]. Nevertheless, only limited information is
available on the possible predictors of pCR by NC, an
issue that is crucial to identify patients who may benefit
from additional treatment. Accumulating data support a
relevant role of host immune responses in mediating the
clinical efficacy of NC, particularly when using drugs
with immunomodulating properties, such as taxanes [6].
Immune activation parameters were significantly associ-
ated with the induction of pCR in HER2-overexpressing
BC patients treated with NC [7]. In particular, the effi-
cacy of trastuzumab in mediating antibody-dependent
cell cytotoxicity (ADCC) [8] is the result of the complex
engagement of different factors, including activating and
inhibitory Fc receptor gene polymorphisms, which have
been correlated with objective response rate (ORR) in
BC patients [9,10]. Interestingly, ADCC efficiency and
the number of circulating natural killer (NK) cells were
related to trastuzumab clinical efficacy in primary oper-
able BC patients [11]. Recent evidence also suggested
that cytokine serum levels might provide useful corre-
lates of the response to NC [12].
This study was designed to assess whether the addition
of trastuzumab in an early phase in combination with
taxanes may increase NC-induced pCR rates in patients
with locally advanced HER2-overexpressing BC without
the burden of cardiac dysfunction related to anthracy-
clines. The rationale of this approach is based on the
consideration that patients usually receive ≥3 cycles of
anthracyclines before starting trastuzumab, with a sig-
nificant delay in the use of the most active drug in this
setting. Moreover, several immune parameters were in-
vestigated throughout NC to assess the contribution of
the immunological background of treated patients to the
induction of clinical responses. The setting of HER2-
overexpressing BC is particularly suited to carry out this
analysis, considering our previous results indicating that
these patients, at diagnosis, retain an unaltered immuneproficiency that can be exploited by NC drugs such as
trastuzumab or taxanes [13].
Methods
Study design and participants
This was a single arm, phase II mono-institutional study.
Patients with HER2-positive locally-advanced BC re-
ceived neoadjuvant weekly paclitaxel (80 mg/m2 on day
1,8,15,22 repeated every 4 weeks [TP]) concurrently with
trastuzumab (loading dose 4 mg/kg intravenously, then
2 mg/kg weekly) for 3 cycles, followed by evaluation
and, in case of clinical response, 3 more cycles were ad-
ministered to obtain pCR. After NC completion, patients
underwent primary surgery (mastectomy or conservative
treatment) and axillary node dissection. After surgery,
adjuvant paclitaxel and trastuzumab was continued for
3 cycles and trastuzumab alone was administered every
3 weeks for 1 year. Radiation and/or hormonal therapy
was performed if indicated. As controls for immune param-
eters, a parallel HER2-negative BC group was prospectively
included and treated with a NC regimen (8 cycles of doce-
taxel [75 mg/m2] and concomitant epirubicin [90 mg/m2]
every 3 weeks [ED]).
The primary outcome was to determine the pCR rate.
pCR was defined as no evidence of microscopic residual
invasive cancer, both in breast and ipsilateral axillary
lymph nodes, or residual carcinoma in situ in the absence
of invasive breast cancer [14]. Secondary endpoints were
ORR, disease-free survival (DFS), overall survival (OS),
and toxicity. This study (CRO-18-2006) was conducted
according to the ethical principles of the Declaration of
Helsinki and approved by the local Ethical Committee
(Comitato Etico Indipendente del CRO di Aviano, may 29,
2006). Written informed consent was obtained from
all patients.
Eligibility criteria were: age ≤ 70 years; histologically
confirmed locally advanced BC (UICC stage II-III, non-
inflammatory) evaluated for HER2/neu status; Eastern
Cooperative Oncology Group performance status of 0
or 1; baseline left ventricular ejection fraction (LVEF) >50%
measured by ultrasonography; adequate organ function
(bone marrow function: neutrophils ≥2.0x109/L, plate-
lets ≥120x109/L; liver function: serum bilirubin <1.5
times the upper normal limit [UNL], transaminases <2.5
times UNL, alkaline phosphatase ≤2.5 times UNL, serum
creatinine <1.5 times UNL) and measurable disease ac-
cording to the Response Evaluation Criteria in Solid
Tumors (RECIST). Exclusion criteria were brain me-
tastases, previous chemotherapy or hormonal therapy,
prior myocardial infarction or uncontrolled arrhythmia
or angina pectoris or other serious medical conditions
or psychiatric syndromes; concurrent malignancy other
than non-melanoma skin cancer, or in situ cervix
carcinoma.
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(including evaluation of vital signs and performance sta-
tus), laboratory tests (haematology and clinical chemis-
try, CA15.3), diagnostic breast imaging (mammogram,
ultrasound, and magnetic resonance imaging), abdominal
ultrasound, bone scintigraphy and LVEF measurement by
echocardiography. Metallic markers were placed into the
breast under ultrasound examination before chemother-
apy. Instrumental evaluation was performed at baseline
and every 12 weeks. RECIST criteria were used to evaluate
the response. Adverse events were graded according to
the National Cancer Institute Common Toxicity Criteria
version 3, and the worst toxicity per cycle was recorded.
LVEF was evaluated every two cycles and cardiac events
were graded according to NYHA.
Surgical evaluation was planned at baseline and at the
end of NC. Patients obtaining a clinical complete re-
sponse or appropriate candidates for breast conservation
therapy (BCT) were offered quadrantectomy, whereas
patients not eligible for BCT underwent total mastec-
tomy. Patients with clinically negative node underwent a
sentinel lymph node biopsy and those who had positive
nodes underwent axillary lymph node dissection. Patients
treated with a segmental mastectomy received whole
breast irradiation after the end of chemotherapy. Radi-
ation treatment of the chest wall and draining lymphatics
was performed in patients with stage III disease and
with ≥4 positive lymph nodes.
The aim of this phase II clinical trial was to show an
increase of a further 20% in the pCR rate (≥40%). The
projected pCR rate with treatment without trastuzumab
was estimated to be ≈ 20% based on previous experience
with similar chemotherapy [15]. Simon’s method was
used to calculate sample size. Accrual of 46 patients was
planned considering an 80% of power to detect a 20% dif-
ference (two-sided type I error = 0.05). The Chi-square
test and Fisher’s exact test were used for qualitative param-
eters. Statistical differences within quantitative parameters
were determined by Wilcoxon rank-test (non-parametric
test) for two samples. Results were considered statistically
significant when P ≤ 0.05 (two-sided). Statistical analyses
were performed with the SAS software (version 9.0).
Immunohistochemistry
Clone 6 F11 and clone 1E2 (Ventana Medical Systems,
Inc., Tucson, AZ) were used for estrogen and progester-
one receptor evaluation, respectively. With the Allred
score, the proportion score and the intensity score are
assessed in six and four grades, respectively 0-5 and 0-3,
then the total score is assessed in eight grades (0 and
2-8) [16]. Tumors with an immunohistochemistry
(IHC) total score of 3 were reported as positive. A score
index of 0, 1, 2, and 3 was used, corresponding to negative,
weak, moderate, and strong staining intensity, respectively,and the percentage of positive cells at each intensity was
estimated subjectively. HER2/neu scores of 0-1 were
considered negative, whereas a score of 3 was reported
as positive (DAKO). Chromogenic in-situ hybridization
or fluorescence in-situ hybridization analyses were per-
formed in cases with IHC total score of 2.Blood sample collection
Heparinised blood and sera were collected from each
patient at diagnosis and throughout NC, after 12 and
24 weeks of treatment. Peripheral blood mononuclear
cells (PBMCs) were freshly isolated from heparinised
blood of patients by Ficoll-Hypaque gradient (Lymphoprep,
Fresenius Kabi Norge Halden, Norway) using standard pro-
cedures and viably frozen at -180°C until use. Serum sam-
ples were obtained with blood centrifugation at 2,100 rpm
and maintained at -80°C.Serum cytokine detection
Levels of interleukin (IL)-1α, IL-1β, IL-2, IL-6, IL-8, IL-10,
IL-12p70, tumor-necrosis factor-α (TNF-α), and granulo-
cyte macrophage colony-stimulating factor (GM-CSF) were
evaluated using the SearchLight® multiplex arrays (Food
and Drug Administration approved, Aushon Biosystems,
TEMA Ricerca, Bologna, Italy) according to the manufac-
turer’s instructions. Briefly, custom human 8-plexarray
and human 1-plexarray (for GM-CSF detection) with
pre-spotted cytokine-specific antibodies were used. Stan-
dards or pre-diluted samples were added in duplicate and,
after 1 hour of incubation at room temperature and 3
washes, biotinylated antibody reagent was added to each
well. After 30 minutes incubation at room temperature
and 3 washes, block solution was added to stabilize the
signal. The addition of Streptavidin-HRP Reagent and
SuperSignal® Substrate, and the acquisition of luminescent
signal with a cooled Charge Coupled Device camera,
together with data analysis and processing, were per-
formed by TEMA Ricerca laboratories’ customer service
(Bologna, Italy). Transforming growth factor (TGF)-β1
serum levels were assessed through ELISA (DRG Instru-
ments GmbH, Marburg, Germany) under manufacturer’s
instructions. Pre-diluted samples and standards under-
went appropriate acidification and neutralization before
testing. Briefly, pre-treated standards, controls and sam-
ples were dispensed into wells in duplicate and plates were
incubated overnight at 4°C. After 3 washes, antiserum was
added to wells and incubated for 120 minutes at room
temperature, plate was rinsed 3 times and anti-mouse
biotin (enzyme conjugate) was dispensed and incu-
bated for 45 minutes. After 3 washes, enzyme complex
was added to wells, plates were incubated 45 minutes
and washed 3 times. After the addition of substrate solu-
tion for 15 minutes, the reaction was stopped and the
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ter plate reader (Bio-Tek Instruments, Winooski, VT, USA).ADCC assay
Trastuzumab-dependent ADCC efficiency was evaluated
in a Calcein release assay, using the Her2/neu-overex-
pressing breast cancer cell line MDA-MB453, authenti-
cated by fingerprinting in November 2013 (Power Plex
1.2, Promega, Madison, WI, USA) as tumor model target
cells, and patients’ PBMCs as effectors. The cell line was
cultured in DMEM (Sigma), containing 2 mM L-glutam-
ine, 10% FBS (Gibco®, Life Technology, Grand Island,
New York, USA), 100 μg/ml streptomycin and 100 IU/ml
penicillin (Sigma-Aldrich, St. Louis, MO, USA), at 37°C in
5% of CO2. One million target cells in exponential
growth was labelled with 7.5 μM Calcein-AM (Molecular
Probes, Eugene, Oregon, USA) for 30 minutes at 37°C,
washed 3 times, then incubated with trastuzumab anti-
body (20 μg/ml; Roche, Basel, Switzerland) 1 h in ice.
Without washing the persistence of soluble antibody, 1 ×
104 labelled target cells per well were seeded into 96-well
U-bottom plates. Experiments were conducted in tripli-
cates at 2 effector (PBMCs):target ratios of 30:1 and 15:1,
in 200 μl of HBSS containing 5% FCS. After 4 h at 37°C
and 5% CO2 the release of Calcein (excitation = 485 nm;
emission = 530 nm) was measured with a fluorescence plate
reader (SpectraFluorPlus, Tecan, Männedorf, Switzerland).
Maximal and spontaneous Calcein release values were
obtained by adding either 100 μl Lysis buffer (NaBO3
0.025 M, Triton X-100 0.1%, pH9) or HBSS, to wells
containing 1 × 104 labelled target cells. The percentage
of lysis was calculated according to the standard for-
mula = 100 × (experimental release – spontaneous re-
lease)/(maximal release – spontaneous release). The
percentage of lysis was normalized for 10,000 NK cells
using the following formula = (percentage of lysis * 104)/
(Effector:Target ratio * target cell n° in an experimental
well * NK percentage in PBMCs) [10].Flow cytometry
The following fluorescent-conjugated monoclonal anti-
bodies were used: α-CD3 phycoerythrin-texas red (ECD;
mouse IgG1, clone UCHT1), and α-CD16 FITC (mouse
IgG1, 3G8), from Beckman Coulter (Fullerton, CA, USA);
α-CD56 phycoerythrin (PE; mouse IgG1 k, B159) pur-
chased from BD Biosciences (Becton Dickinson, Franklin
Lakes, NJ, USA). Properly labelled isotypic antibodies
were used as negative controls. All antibodies were used
in an appropriate volume of 10% rabbit serum (Dako,
Glosdrup, Denmark) and PBS (Biomerieux, Marcy l’Etoile,
France) to reduce unspecific signal. At least 10 × 104 cells
were acquired. Flow cytometry analysis was performed
with a Cytomics FC500 (Beckman Coulter, Fullerton,CA, USA) and data were analyzed with CXP software
(Beckman Coulter, Fullerton, CA, USA).
Analysis of FcγRIIIa, FcγRIIa, and FcγRIIb polymorphisms
Genomic DNA was purified using DNA extraction kit
(EZ1 DNA Blood 350 μl kit, Qiagen, Valencia, CA) from
blood samples obtained at diagnosis from all patients.
FcγR locus genotyping was performed on the genomic
DNA of 37 patients by polymerase chain reaction (PCR)
followed by direct sequencing in both forward and re-
verse directions, focusing on the hot spots of SNPs at
FcγRIIa-131, FcγRIIIa-158, and FcγRIIb-187. All PCR re-
actions were conducted with 250 ng of DNA, 10pmol of
each primer, 1.5 mM MgCl2, 10 mM dNTPs, and 2.5 unit
of Taq DNA polymerase (all reagents purchased from Pro-
mega) in a 50 μl reaction volume. The FcγRIIIa-158 V/F
polymorphism was investigated through a nested PCR
first using the forward primer 5′-TTGAAGGCCATGCT
CAGTAAT-3′ and the reverse primer 5′-AGGCTGGTG
CTACAGAACCTA-3′ to amplify a fragment of 1699 bp.
The PCR reaction was started at 95°C for 5 minutes,
followed by 35 cycles of denaturing at 94°C for 30 seconds,
annealing at 68°C for 90 seconds, and extension at 72°C
for 90 seconds, with a final extension at 72°C for 10
minutes. PCR products were diluted 1:10 and 1 μl was
used for the nested PCR employing the following
primers: forward 5′-TTACAGAATGGCAAAGGCAG-3′,
reverse 5′-TCTCCTCCCAACTCAACTTCC-3′. The PCR
reaction was performed starting at 95°C for 5 minutes, and
subsequent 35 cycles of denaturing at 94°C for 30 seconds,
annealing at 65°C for 45 seconds, extension at 72°C for
60 seconds, and a final extension for 10 minutes at 72°C.
The PCR product of 238 bp was purified and directly se-
quenced using the BigDye Terminator sequencing kit and
an ABI Prism 3100 sequencer (both from Applied Biosys-
tems, Foster City, CA). The FcγRIIa-131H/R polymor-
phisms was analysed through a single PCR followed by
sequencing using the forward primer 5′-CTGGTCAAG
GTCACATTCTTC-3′ and the reverse 5′-CAATTTTG
CTGCTATGGGC-3′, performing 35 cycles of denaturing
at 94°C for 30 seconds, annealing at 50°C for 30 seconds,
extension at 72°C for 30 seconds, and a final extension for
10 minutes at 72°C amplifying a 277 bp fragment [17].
Finally, the FcγRIIb-187I/T polymorphism was investi-
gated in PCR and then sequenced using the forward
5′-CTCTGTTCCTGCCTGCTCACA-3′ and the reverse
primer 5′-CTGGCAATGTCTGGGGTTAGG-3′, obtain-
ing a 430 bp fragment from a PCR reaction of 35 cycles of
denaturing at 94°C for 30 seconds, annealing at 60°C for
45 seconds, extension at 72°C for 60 seconds.
Statistical methods for immunological studies
The Student’s t test for two tailed distributions and paired
data was used for the statistical analysis of cytokine serum
Table 1 Patient characteristics at baseline
Characteristics Trastuzumab (T) +
paclitaxel (P) (n = 46)
Epirubicin (E) +
docetaxel (D) (n = 58)
Median age, years 46 46
Range 23 - 70 27 - 69
Hormone receptor
status
ER+ and PgR+ 13 33
ER+ and PgR- 9 9
ER- and PgR- 21 15


















Abbreviations: ER = estrogen receptor; PgR = progesterone receptor;
HER2 = human epidermal growth factor receptor-2; CISH = chromogenic
in situ hybridization; FISH = fluorescence in situ hybridization.
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comparing data obtained at diagnosis with data mea-
sured respectively after 12 and 24 weeks of treatment.
The non-parametric Kruskal-Wallis test for the com-
parison of three independent samples was employed to
investigate the ADCC lysis (absolute and normalized)Table 2 Response Rates to NC incorporating trastuzumab
N PD
Total 46 (100%) 2 (4.4%) 23
ER status
Positive 22 (47.8%) 13
Negative 24 (52.2%) 2 (8.3%) 10
Stage distribution
IIA 6 (13%) 1(16.6%) 4 (
IIB 27 (58.7%) 13
IIIA 12 (26.1%) 1 (8.3%) 5 (
IIIB 1 (2.2%) 1 (
Abbreviations: PD = progression disease; cPR = clinical partial response; cCR = clinic
breast pathological complete response.percentages classified by the FcγRIIIa158 polimorph-
ism (genotypes V/V, V/F, and F/F). The non-parametric
Wilcoxon test for two independent samples was applied
to compare ADCC lysis (absolute and normalized) per-
centages of V carriers with those of F/F individuals. Data
obtained from multiple independent experiments were
expressed as mean and standard deviation. Differences
were considered statistically significant when P ≤ 0.05.Results
Clinical response
From July 2006 to February 2013, a total of 109 patients
were enrolled (Table 1). Three patients were excluded
due to discordant pre- and post-operative HER2 status.
In the HER2-negative group, one patient discontinued
the trial due to adverse events (nausea-vomiting G4,
diarrhoea G3, and neutropenic fever G4 on cycle 1) and
one was lost on the post-surgical follow-up.
Clinical response data for HER2-positive patients are sum-
marized in Table 2. Twenty-three pCR (50%) were achieved,
with residual ductal carcinoma in situ in 7 patients. By
intent-to-treat analysis after median follow-up of 42.9 months
(7.5-84.2 months), 10 primary outcome events were re-
ported, whereas the median DFS was not reached. Also the
median OS was not reached after median follow-up time of
47.3 months (7.5-84.2 months) (Figure 1). At the end of
treatment, all patients underwent surgery. Breast conserving
surgery rate was 39.1% (18/46).Safety data
The adverse events observed in the HER2-positive group
are reported in Table 3. Three patients experienced grade
3 onychopathy and only one patient developed onychopa-
thy that progressed to grade 4. One patient developed a
peripheral neuropathy grade 3, whereas all other adverse
events were generally mild. Because of onychopathy and
peripheral neuropathy, 3 patients needed dose reductions.
Of note, none of these patients developed symptomaticcPR cCR tpCR bpCR
(50%) 21 (45.6%) 23 (50%) 26 (56.5%)
(59%) 9 (41%) 10 (45.4%) 12 (54.5%)
(41.7%) 12 (50%) 13 (54.2%) 14 (58.3%)
66.8%) 1 (16.6%) 5 (83%) 5 (83%)
(48%) 14 (52%) 11 (41%) 14 (52%)
41.7%) 6 (50%) 7 (58.3%) 7 (58.3%)
100%)
al complete response; tpCR = total pathological complete response; bpCR =
Figure 1 Disease-free survival and Overall survival. A. Disease-free survival and B. Overall survival in the HER2-positive group.
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were not reported.
Serum cytokine profiling
Serum levels of 10 different cytokines were evaluated at
diagnosis, after 12 and 24 weeks in 25 HER2-positive and
in 36 HER2-negative patients. No significant changes were
highlighted in the HER2-positive group for any of the
cytokines investigated throughout NC treatment, whereas
significant alterations were observed in HER2-negative pa-
tients during ED chemotherapy (a decrease in IL-2, GM-
CSF, IL-1α [P = 0.01], IL-1β [P = 0.03], and IL-6 amounts[P = 0.03] after 12 weeks, a decrease in the levels of GM-
CSF, IL-1α [P = 0.01], and IL-10 [P = 0.04] after 24 weeks,
and increase in IL-6 levels [P =0.02] at 24 weeks of NC)
(Figure 2A).
Comparison of HER2-positive patients undergoing pCR
with those achieving partial responses disclosed a signifi-
cant decrease in IL-10 levels (P = 0.02) after 12 weeks of TP
therapy only in partial responders (Figure 2B). Similarly,
altered cytokine levels were more frequently observed
in HER2-negative patients with partial pathological re-
sponses (a decrease in the levels of IL-2 and IL-1α [P =
0.02] at 12 weeks, a decrease in IL-12p70 [P = 0.05], IL-1α
Table 3 Worst hematological and non-hematological toxic
effects in 46 HER2-positive BC patients








Mucositis 7 2 1





Peripheral neuropathy 13 15 1
Onychopathy 6 12 3 1
Arthralgia - myalgia 5 1
Oedema legs 8 1
Skin toxicity 3 2
Flush 2 6
Epistaxis 3
Left ventricular dysfunction 4
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increase in IL-6 levels [P = 0.03] after 24 weeks of NC)
(Figure 2C). Patients achieving pCR after ED therapy
revealed a significant decrease in IL-8 levels (P = 0.02)
at week 12 (Figure 2C).
Integrated immunomonitoring of Trastuzumab-mediated
ADCC activity
Thirty-seven HER2-positive patients were genotyped for
the FcγRIIIa-158 valine (V)/phenylalanine (F), the FcγRIIa-
131 histidine (H)/arginine (R), and the FcγRIIb-187 isoleu-
cine (I)/threonine (T) polymorphisms. No significant
correlations with pCR were found for any of the poly-
morphisms analyzed (not shown).
Assessment of the ability of patients’ PBMCs to medi-
ate trastuzumab-mediated ADCC showed a gradient of
efficiency according to the FcγRIIIa-158 genotypes, with
V/V > V/F > F/F at all time points investigated and a
significant difference observed at diagnosis (P = 0.01;
Figure 3A). The gradient in lysis efficiency was still ob-
served after normalization for the number of NK cells, the
main ADCC mediators [11], with significant differences
both at diagnosis (P = 0.01) and at week 12 (P = 0.04;
Figure 3A). Notably, the number of circulating NK cellsincreased along the NC treatment, with a difference that
was statistically significant after 24 weeks only in V/V
patients (P = 0.01; Figure 3A). V carriers (V/V + V/F)
had effectors eliciting a higher percentage of ADCC
lysis at diagnosis compared to F/F patients (P < 0.01),
showed a significant increase in the number of circu-
lating NK cells after 24 weeks (P = 0.01), and maintained
a higher ADCC efficacy (normalized lysis) at diagnosis
and throughout NC (P = 0.01 at diagnosis; P = 0.02 at
week 12; P = 0.05 at week 24) with respect to patients
carrying the unfavourable genotype (Figure 3B).
Discussion
This study confirms that an anthracycline-free NC regimen
for locally advanced HER2-positive BC patients can be
safely used without compromising the clinical outcome,
provided that trastuzumab is given concurrently with a
weekly taxane. The 50% pCR rate observed in our study is
highly promising considering that similar outcomes have
been previously obtained only with anthracycline-containing
regimens [1,3,4]. Moreover, between HER2-negative and
HER2-positive BC, a difference of 36% in pCR rate was
observed. These results are in line with those shown in
the NOAH trial in which a difference of 26% in pCR
rate between HER2-positive (43%) and HER2-negative
(17%) BC was detected [3,4].
Our findings are particularly relevant in the light of
the recent demonstration that, in selected groups of pa-
tients, chemotherapy could be entirely avoided. In fact,
in the NeoSphere study, Trastuzumab/Pertuzumab com-
bination yielded a 16.8% pCR rate, which increased up
to 29% in the ER/PgR-negative subgroup [18]. Moreover,
in the NeoALTTO study, the double HER2 block in-
duced by Trastuzumab/Lapatinib combination showed
significant clinical response rates 6 weeks before starting
chemotherapy [16]. Our results provide also possible in-
dications regarding the chemotherapeutic backbone as-
sociated with trastuzumab, a still open issue in relation
to efficacy and safety, especially considering long-term
outcomes. In fact, while pCR rate obtained by trastuzu-
mab in combination with paclitaxel administered every
three-weeks was only 18% in stage II/III BC [19], our re-
sults are consistent with a more synergic activity of tras-
tuzumab when associated with paclitaxel in the weekly
schedule [20].
Besides showing clinical efficacy, our anthracycline-
free NC regimen was not burdened by severe cardiac
toxicity. In fact, no patients developed symptomatic con-
gestive heart failure and only 4 patients showed a LVEF
grade 1 reduction. Although limited by the small number
of patients enrolled and by median follow up with a wide
confidence interval, we report an 8.6% rate (4 out of 46) of
asymptomatic cardiotoxicity, which is in line with previ-
ous studies, and a lower incidence of symptomatic cardiac
Figure 2 (See legend on next page.)
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Figure 2 Serum cytokine profile. Interleukin (IL)-2, IL-12p70, IL-1α, IL-1β, IL-8, IL-6, IL10, and granulocyte-macrophage colony-stimulating factor
(GM-CSF) levels were evaluated in serum samples from HER2-negative (n = 36) and HER2-positive (n = 25) patients at diagnosis, and at the 12° and
24° weeks (W) of NC treatment. A. Trend of cytokine levels throughout NC in the 2 groups of treatment. Box plots represent the median values, the
25th, and the 75th percentiles. B. IL-10 levels in HER2-positive patients achieving a complete (n = 13) or a partial (n = 12) pathological response. Each
circle symbolizes the IL-10 concentration measured in each patient. The mean value is indicated. C. Cytokine levels in HER2-negative patients
divided in individuals achieving a complete (n = 5) or a partial (n = 31) pathological response. Statistical analysis was performed with the
Student’s t test; *P < 0.05. HER2, human epidermal growth factor receptor-2. HER2+, HER2-positive patients. HER2−, HER2-negative patients.
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http://www.biomedcentral.com/1471-2407/14/954events than expected (0.74-1.9). In the NOAH trial, the
concurrent use of doxorubicin and trastuzumab was asso-
ciated with an incidence of cardiac events lower (<2%)
than expected on the basis of adjuvant trials results with
trastuzumab and anthracyclines [3,4]. Indeed, the duration
of trastuzumab and the limited exposure to epirubicin con-
comitantly with trastuzumab could have influenced the
cardiac safety, as demonstrated by previous findings report-
ing no clinical congestive heart failure [1]. In this context,
our results indicate that the trastuzumab-paclitaxel com-
bination represents a well-tolerated and heart-safe regimen,
consistently with previous studies on anthracycline-free ad-
juvant regimens in HER2-positive BC [21]. In addition, our
data are in keeping with those recently reported at the
2013 San Antonio Breast Cancer Symposium with theFigure 3 Monitoring of Trastuzumab-mediated ADCC activity in HER2
Representative data obtained against the HER2-overexpressing cell line MD
and 24° weeks (W) of NC treatment. A. Data were classified by the V/V (n =
ism. Statistical analysis was performed with the Kruskal-Wallis test. B. Analys
through the Wilcoxon test. Graphs on the left show the absolute percentag
cells were identified in flow cytometry as CD3-CD16 + CD56dim lymphocyt
10,000 NK cells. Data are represented as means and standard deviations. Th
*Chi-square or |Z| < 0.05. **P < 0.05. HER2, human epidermal growth factorsame regimen in 406 node-negative HER2-positive patients
treated in the adjuvant setting [22]. The impressive results
obtained without anthracyclines, at least in a selected
population of patients, may become “practice-changing” in
the next few years.
Achievement of pCR in patients with HER2-
overexpressing BC was associated with better distant
metastasis-free survival, recurrence-free survival, DFS and
OS [15,23,24]. In our study, only 3 of the 10 HER2-
positive patients showing a recurrence had previously
achieved a pCR. Extended follow-up is needed to reach
the median DFS and OS, and to draw definite conclu-
sions. In this respect, while in the absence of trastuzu-
mab NC including anthracyclines still induces superior
outcomes [25], a recent paper by Guiu and colleagues-positive patients according to the FcγRIIIa polymorphism.
A-MB-453 using patients’ PBMCs collected at diagnosis, and at the 12°
9), V/F (n = 17), and F/F (n = 10) genotypes of the FcγRIIIa polymorph-
is was performed comparing V carriers (n = 26) with F/F individuals,
e of lysis measured at a 30:1 Effector:Target ratio. Natural Killer (NK)
es. Histogram plots on the right display normalized lysis calculated for
e Student t test was employed for NK cells percentage variations.
receptor-2.
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OS in locally advanced HER2-positive BC patients
treated with anthracycline-free trastuzumab-based NC.
Immune profiling of our series of patients with HER2-
overexpressing BC demonstrated a retained immune pro-
ficiency at diagnosis [13]. Consistently, here we show that
the same patients had unaltered cytokine levels during TP
therapy, suggesting that the clinical benefit achieved by
trastuzumab and taxanes may partially rely on the immune-
mediated mechanisms of these drugs [27]. Conversely, in
the HER2-negative cohort, which is different from the
HER2-positive arm for the biology of the tumor, the NC
treatment, and also for the immune profile at diagnosis [13],
we observed changes in IL-1α, IL-1β, IL-2, IL-6, and GM-
CSF levels already at week 12 of ED treatment. Intriguingly,
the only cytokine abnormality observed in the HER2-
positive group, a decrease in IL-10 levels, was restricted to
patients undergoing partial pathological responses. IL-10 is
a pleiotropic cytokine, which may favour NK cell-dependent
lysis through MHC class-I down-regulation on tumor cells
[28,29]. This potential effect of IL-10 may synergize with the
ability of taxanes to increase NK cell activity [6], and could
support a correlation between pCR and maintained IL-10
levels.
NK cells are key factors for an efficient trastuzumab-
mediated ADCC [27]. We noticed, at diagnosis, different
ADCC efficacy among patients carrying the V/V, V/F, or
F/F genotypes of the activating FcγRIIIa receptor. This
polymorphism correlated with improved clinical responses
observed after trastuzumab in some instances but not in
others [9,30]. Notably, comparing the 3 FcγRIIIa-158
genotypes, we observed different levels of normalized
ADCC at diagnosis, suggesting the primary role of NK
cells in mediating trastuzumab efficacy and the func-
tional relevance of the FcγRIIIa-158 polymorphism.
We also noticed that patients carrying the favourable V
allele maintained a high ADCC efficiency (normalized
lysis) throughout the NC treatment, and showed a sig-
nificant increase in NK cell percentage after 24 weeks
of therapy. These findings are consistent with a syner-
gistic activity between trastuzumab and taxanes, par-
tially dependent on immune mechanisms [8,31], and
are in keeping with the reported ability of this drug
combination to promote NK cell recruitment and acti-
vation [32]. Conversely, the concurrent chemotherapy
with anthracyclines or alkylating agents seemed to dimin-
ish the influence of the FcγRIIIa genotype on patients’ out-
come when treated with trastuzumab [30]. Intriguingly,
previous findings demonstrating an association between
trastuzumab-mediated ADCC and a favourable outcome
in operable HER2-overexpressing BC patients supported
the importance of an uncompromised immune function
in patients with early-stage tumors [6,11]. With this phase
II study, we demonstrated that patients with locallyadvanced HER2-overexpressing BC still maintain an im-
mune proficiency that could be exploited by drugs acting
synergistically through immune-mediating mechanisms.Conclusions
In conclusion, the present phase II study reports a high
rate of pCR in locally advanced HER2 overexpressing BC
patients treated with a NC regimen excluding anthracy-
clines and combining trastuzumab and paclitaxel in a
weekly schedule. This therapeutic choice is characterized
by a low toxicity as demonstrated by the reduced cardio-
toxicity and the maintained immune proficiency in BC
patients. Our results are consistent with the possibility
that the synergy between the immunomodulating proper-
ties of the drugs used in this trial and the retained im-
mune competence observed in BC patients may favor the
induction of pCR. In perspective, longer follow-up of our
cohort of patients will provide evidence supporting the
possible correlation between the high pCR rate obtained
with anthracycline-free NC regimen and both a longer
disease-free interval, and a definite low risk of cardiotoxi-
city. Furthermore, immunomonitoring of follow-up pa-
tients will reveal whether the immunological parameters
identified in this study may be regarded as biomarkers po-
tentially able to predict the clinical outcome of locally ad-
vanced HER2-overexpressing BC patients treated with
regimens devoid of anthracyclines.
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